Drugs / IBI3013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07554222 | Apr 2026 → Dec 2027 expected | alopecia areata, vitiligo | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07554222 ↗ |
| Action | Inhibit | “anti-Interleukin-15 (IL-15)” NCT07554222 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-Interleukin-15 (IL-15) monoclonal antibody injection” NCT07554222 ↗ |
| Route | Intravenous | “subcutaneous injection/intravenous infusion,single or multiple dosing” NCT07554222 ↗ |
| Route | Subcutaneous | “subcutaneous injection/intravenous infusion,single or multiple dosing” NCT07554222 ↗ |